Background: Central nervous system (CNS) metastases are common in patients with non-small-cell lung cancer (NSCLC). Osimertinib has shown systemic efficacy in patients with CNS metastases, and early clinical evidence shows efficacy in the CNS. To evaluate osimertinib activity further, we present a pre-specified subgroup analysis of CNS response using pooled data from two phase II studies: AURA extension (NCT01802632) and AURA2 (NCT02094261).
Introduction
Central nervous system (CNS) metastases are common in patients with advanced non-small-cell lung cancer (NSCLC) and have a negative impact on survival and quality of life (QoL) [1] . Many chemotherapeutic agents are unable to penetrate the blood brain barrier (BBB); therefore, the CNS is a sanctuary site for metastatic spread [2] . Treatment options for limited brain metastases from NSCLC include surgical resection and stereotactic radiosurgery (SRS), while whole-brain radiotherapy (WBRT) is recommended for multiple brain metastases [3, 4] . However, recent evidence suggests that WBRT does not significantly improve survival or QoL compared with supportive care alone [5] . The potential long-term adverse effects of WBRT on neurocognitive function are also a concern [3, 6] . SRS avoids the adverse effects on cognition and QoL associated with WBRT [7] and provides effective local control of brain metastases [8] . However, SRS is costly [9] and, if used alone, carries a risk of failure in non-treated brain regions [10] .
Approximately 25% of patients with epidermal growth factor receptor (EGFR)-mutated NSCLC present with CNS metastases at first diagnosis [11] . Patients treated with EGFR-tyrosine kinase inhibitors (TKIs) show a lower risk of progression in the CNS, compared with chemotherapy [12] , and the presence of EGFR-TKI-sensitising mutations (EGFRm) is associated with better responses to EGFR-TKI treatment in patients with NSCLC and CNS metastases, compared with EGFR wild-type disease or unknown EGFR-mutation status [13] . However, despite the use of EGFR-TKIs, the incidence of CNS metastases increases to more than 45% of patients 3 years after diagnosis [11] . As patients are living longer, there is an increasing need for therapeutics that can ensure control within the sanctuary CNS site.
Osimertinib is a potent, oral, CNS-active, irreversible EGFR-TKI selective for both EGFRm and EGFR T790M resistance mutations [14] . Osimertinib treatment is recommended for patients with EGFR T790M-positive NSCLC who have progressed on EGFR-TKI therapy [3] . In a pooled analysis of the phase II AURA extension (NCT01802632) [15] and AURA2 (NCT02094261) [16] studies, osimertinib demonstrated an objective response rate (ORR) of 66% [95% confidence interval (CI) 61% to 71%] [17] . In the confirmatory phase III trial (AURA3, NCT02151981), osimertinib demonstrated significantly greater efficacy than chemotherapy [18] . Osimertinib has demonstrated systemic efficacy in patients with CNS metastases [15, 16, 18] and CNS activity has been reported previously in the AURA extension trial (n ¼ 25) [15] . Here, we present a larger, pre-specified, pooled, subgroup analysis to further evaluate CNS response to osimertinib in the AURA extension and AURA2 phase II studies.
Methods

Trial design and treatment
This was a pre-specified subgroup analysis of CNS response to osimertinib from pooled data from two global, single-arm, phase II, open-label studies of osimertinib in patients with T790M-positive advanced NSCLC, who had progressed following prior therapy with an EGFR-TKI (AURA extension and AURA2). Full details of the methodology for each study have been published previously [16, 19] . Patients received osimertinib 80 mg p.o. od until disease progression [as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1] or until a discontinuation criterion was met (supplementary Methods, available at Annals of Oncology online). Baseline brain scans by magnetic resonance imaging or computed tomography were mandatory only in those patients with known or suspected CNS metastases at study entry. Submitted baseline brain scans were assessed for the presence of CNS metastases by neuroradiological blinded independent central review (BICR). For patients with evidence of CNS metastases, follow-up brain scans were required every 6 weeks. Per protocol, if disease progression was confirmed by independent assessment (in the primary assessment of systemic response), no further scans were required. On discontinuation of osimertinib, RECIST assessments continued every 6 weeks until disease progression, regardless of further treatment. Only patients with !1 measurable lesion (according to RECIST 1.1) on baseline brain scan by BICR were included in the evaluable for CNS response set (cEFR). Patients with radiologic evidence suggestive of leptomeningeal metastases (LM) on baseline brain scans were assessed for LM response by neuroradiological BICR.
Participants
In brief, adult patients with EGFR T790M-positive NSCLC who had progressed on prior EGFR-TKI therapy were eligible for inclusion. Patients with asymptomatic, stable brain metastases not requiring corticosteroids for at least 4 weeks before study entry were eligible for inclusion, including those patients with LM; prior CNS treatment was allowed. There were no exclusion criteria for treatment before the 4 weeks immediately before study entry, aside from previous treatment with osimertinib (AURAext; AURA2) or a third-generation EGFR-TKI (AURA2).
Ethics
The studies were approved by institutional review boards or independent ethics committees at all study centres, and carried out in accordance with the ethical principles that have their origin in the Declaration of Helsinki and are consistent with the International Conference on Harmonisation/ Good Clinical Practice and applicable regulatory requirements.
Assessments
The primary outcome for this pre-specified CNS analysis was CNS ORR by BICR. Secondary outcomes included CNS disease control rate (DCR), CNS duration of response and CNS progression-free survival (PFS), and change from baseline in the sum of CNS target lesion (TL) size. The effect of prior radiotherapy on CNS response to osimertinib was assessed. CNS ORR by BICR and tumour shrinkage were assessed according to RECIST. For the CNS analysis, measurable CNS metastases on BICR were designated as TL and non-measurable CNS lesions as non-target lesions (NTL) for response assessment. As such, LM were assessed as NTL for the assessment of CNS response. In the primary analysis of the overall pooled AURA extension and AURA2 population, all CNS lesions were designated NTL for RECIST response assessment. LM response was assessed in accordance with the radiographic criteria proposed by the Response Assessment in Neuro-Oncology (RANO) LM working group [20] (supplementary Methods and Table S1 , available at Annals of Oncology online).
Statistical methods
The data cut-off for the CNS analysis was 1 November 2015. The cEFR was defined as all patients with at least one measurable lesion on baseline brain scan by BICR. For definitions of end points, see supplementary Methods, available at Annals of Oncology online.
Results
Patients
Of 411 patients treated across the two phase II studies, 192 had a brain scan at baseline, including 128 patients with evidence of CNS metastases by BICR. Fifty patients had at least one CNS TL and were included in the cEFR set ( Figure 1 ). Baseline demographics in the cEFR were broadly consistent with the overall patient population, although patients with measurable CNS disease tended to have a poorer World Health Organization (WHO) performance status (supplementary Table S2 , available at Annals of Oncology online). Thirty-seven patients (74%) received brain radiotherapy before study treatment ( 6 months: n ¼ 19; >6 months, n ¼ 18). Seven (15%) patients had radiologic evidence suggestive of LM. The median duration of osimertinib treatment was 12 months (range, 1.5-17.1 months).
Efficacy
CNS response. At data cut-off, confirmed CNS ORR was 54% (27/50; 95% CI 39% to 68%) with complete responses reported in six patients (12%) ( Table 1) . Median best percentage change from baseline in CNS TL size was À53% (range, -100% to þ80%) (Figure 2A ). The CNS DCR was 92% (46/50; 95% CI 81% to 98%). Of those patients experiencing a CNS response, the majority (81%) had responded by the time of first assessment (6 weeks). Median CNS duration of response was not reached [95% CI not calculable (NC); range, 1-15 months]; 6/27 patients with an objective CNS response subsequently progressed in the CNS or died in the absence of progression (22% maturity). The proportion of patients estimated to be remaining in response at 3, 6 and 9 months after onset of response was 100% (95% CI 100% to 100%), 80% (95% CI 59% to 91%) and 75% (95% CI 53% to 88%), respectively ( Figure 3A) . CNS responses were observed regardless of prior brain radiotherapy (Table 1) . Following initiation of osimertinib treatment, only
Patients with baseline brain scan (MRI/CT) evaluated by neuroradiologist BICR n=192
Patients with no CNS lesions n=64
Patients with only non-measurable CNS lesions n=78
Patients with ≥1 measurable CNS lesion n =50
Patients with CNS lesions (measurable and/or non-measurable) by RECIST 1.1 n =128 Figure 1 . Study design. Concordance between CNS and systemic response. Thirty-two of 50 patients (64%) in the cEFR had a systemic response to osimertinib by RECIST 1. Original article Annals of Oncology systemic response to osimertinib was 54%: 18/50 patients (36%) had both a CNS and systemic response, and 9/50 patients (18%) were non-responders [stable disease (SD), progressive disease or not evaluable] both systemically and in the CNS (supplementary Table S5 , available at Annals of Oncology online). Changes in CNS tumour size from baseline were well correlated with best overall systemic responses ( Figure 2B ). Most patients with a best overall systemic response of partial response showed a consistent decreasing trend in CNS TL size. In patients with a best overall response of SD, CNS responses were either SD or partial response across the duration of treatment, suggesting that progression was not mediated by CNS lesions.
CNS PFS. Median follow-up for CNS PFS in the cEFR was 11 months; median CNS PFS was not reached (95% CI 7 to NC).
The proportion of patients remaining progression free was 72% (95% CI 57% to 83%) at 6 months and 56% (95% CI 40% to 70%) at 12 months (Table 1; Figure 3B ). Overall, 19 of 50 patients experienced a progression event: 12 (63%) had CNS progression and seven (37%) died in the absence of CNS progression. To test for potential bias in the analysis of CNS PFS in the cEFR, a CNS PFS analysis was conducted using all CNS progression data for the pooled phase II studies, regardless of CNS metastases status at baseline (supplementary Results, available at Annals of Oncology online); results were consistent with the CNS PFS analysis for the cEFR.
Safety
The safety profile of osimertinib in the cEFR was consistent with the safety profile in the overall patient population (supplementary Table S6 , available at Annals of Oncology online). All patients in the cEFR reported at least one adverse event (AE) and 43 (86%) reported a possibly causally related AE, as assessed by investigator. CTCAE Grade 3 or greater possibly causally related AEs occurred in six patients (12%) [21] . One patient (2%) experienced an AE (grade 3 interstitial lung disease) with an outcome of death possibly causally related to study treatment.
Discussion
In this pooled analysis of two single-arm phase II studies, osimertinib demonstrated clinically meaningful activity in patients with T790M-positive NSCLC and CNS metastases. Osimertinib demonstrated an encouraging CNS ORR of 54% with a rapid onset of response and CNS DCR of 92%. Systemic ORR and safety were consistent with that reported for the overall patient population. The results of this pooled analysis support previous results, which demonstrated the efficacy of osimertinib in patients with CNS metastases [16] . CNS PFS with osimertinib is encouraging; however, mature CNS PFS data are not available, as patients did not continue to receive brain scans following disease progression (irrespective of site of progression) or discontinuation from study. As such, one limitation of the CNS PFS analysis is that the observed treatment benefit may be overestimated; however, results of the CNS PFS analysis of the overall population were consistent with the analysis of the cEFR. Osimertinib activity in seven patients with suspected LM based on radiologic features was encouraging. The role of osimertinib (160 mg od) in patients with LM from NSCLC is further being investigated in the BLOOM study (NCT02228369); preliminary results indicate promising activity and manageable tolerability [22] . Patients with CNS metastases are frequently excluded from clinical trials; therefore, there is limited evidence regarding the efficacy of first-and second-generation EGFR-TKIs in the CNS [23] . In a retrospective review of patients with brain metastases from EGFR/ anaplastic lymphoma kinase-driven NSCLC, median time to intracranial progression with TKIs was similar to that achieved with SRS (15 versus 12 months, respectively), but shorter than with WBRT (50.5 months); there was no difference in overall survival [24] . As the cerebrospinal fluid penetration of erlotinib and gefitinib is limited, high-dose administration is sometimes used in an attempt to increase levels in the cerebrospinal fluid [25, 26] . Previous research has suggested that radiotherapy may facilitate the CNS penetration of systemic therapies by altering BBB permeability [27] . However, CNS responses to osimertinib were observed regardless of prior radiotherapy status. While the observed ORR was higher in patients who had no prior brain radiotherapy or radiotherapy !6 months before osimertinib, compared with patients who received radiotherapy 6 months before osimertinib, these data should be interpreted with caution given the overlapping CIs and the low number of patients in each subgroup.
Osimertinib treatment is now recommended for patients with brain metastases from T790M-positive NSCLC [3] . Before this, the recommended treatment options for patients with CNS metastases from NSCLC were limited to surgery and SRS or WBRT [28] . Osimertinib offers patients with CNS metastases an additional line of treatment and may allow patients to avoid the adverse effects associated with WBRT. While all patients in this study had T790M-positive NSCLC, the T790M status of patients' CNS disease was not assessed. Published data suggest that T790M may occur less frequently in CNS metastases than in the primary tumour [29] ; therefore, some patients in our study may have had T790M-negative CNS metastases. In such patients, osimertinib would be acting against EGFR-TKI sensitising mutations rather than the T790M resistance mutation. In the recent FLAURA (NCT02296125) study, osimertinib demonstrated superior efficacy versus standard-of-care EGFR-TKI as first-line therapy in patients with advanced EGFRm NSCLC, including those patients with known or treated CNS metastases at study entry [30] .
In summary, osimertinib demonstrated clinically meaningful efficacy in patients with CNS metastases, with a high CNS DCR and encouraging CNS ORR, consistent with the systemic response to osimertinib. Osimertinib offers an additional line of treatment of patients with T790M-positive NSCLC and CNS metastases.
